Prevention of allergic reactions during oxaliplatin desensitization through inhibition of Bruton tyrosine kinase
Acute infusion reactions to oxaliplatin, a chemotherapeutic used to treat gastrointestinal cancers, are observed in about 20% of patients. Rapid drug desensitization (RDD) protocols often allow the continuation of oxaliplatin in patients with no alternative options. Breakthrough symptoms, including anaphylaxis, can still occur during RDD.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Kristin A. Erickson, James E. Norton, Jennifer Law, Nicole Soriano, Malgorzata Strojny, Nicole Gentry, Morgan Fried, Bruce S. Bochner, Sheetal Kircher, Whitney W. Stevens Tags: Brief report Source Type: research
More News: Allergy | Allergy & Immunology | Anaphylactic Shock | Cancer | Cancer & Oncology | Eloxatin | Gastroenterology